Pharma
Bioactive formulations and receptor kinetics engineered from scratch, in Perth, Western Australia.
Scroll to review formulations
The scene: a concrete caisson in the shape of the Caisson mark floats in a green river.
Anterosa
Anterosa is an extended-release formulation of lisdexamfetamine dimesylate (50 to 70 mg). It converts gradually in the bloodstream rather than releasing active stimulant all at once, providing smooth monoamine availability that prevents sudden peaks and midday drop-offs.
- 12-14 h
- Therapeutic arc for continuous working stamina.
- 50-70 mg
- Flexible daily titration window.
Extended-release dopamine and norepinephrine activator engineered for continuous daytime stamina and executive clarity.
Anterosa formulation chapter.
Tarvelo
Tarvelo is an immediate-release tablet of clonidine hydrochloride (100 mcg). It acts on presynaptic alpha-2A autoreceptors in the brain stem to moderate adrenaline output, calming peripheral tension and stabilizing cardiovascular rhythm without dulling cognitive focus.
- 100 mcg
- Fast-acting central sympatholytic payload.
- 30-60 min
- Rapid onset for acute sympathetic stabilization.
Central alpha-2A autoreceptor agonist designed to rapidly quiet adrenaline outflow and steady cardiovascular tone.
Tarvelo formulation chapter.
Canaryl
Canaryl is an immediate-release tablet of methylphenidate hydrochloride (10 mg target). It selectively inhibits dopamine and norepinephrine reuptake carriers in the frontal cortex, providing a clean morning surge in task initiation drive without cellular depletion.
- 10 mg
- Nominal target payload for acute morning initiation.
- 20-30 min
- Fast onset with a focused 3 to 4 hour working arc.
Rapid-onset dopamine and norepinephrine reuptake inhibitor for clean morning task initiation.
Canaryl formulation chapter.
Thresha
Thresha is an extended-release matrix capsule of methylphenidate hydrochloride (40 mg). Its progressive dissolution profile matches daytime metabolic curves, ensuring uninterrupted dual monoamine transport inhibition that keeps focus locked in through peak afternoon hours.
- 40 mg
- Fixed assay payload for sustained transport inhibition.
- 8-10 h
- Continuous focus matched to peak daytime demands.
Extended-release dual monoamine reuptake inhibitor engineered for locked baseline midday focus.
Thresha formulation chapter.
Zentraxyl
Zentraxyl is a sublingual transmucosal tablet of buprenorphine (200 mcg). It modulates opioid receptors with high affinity but partial activation, easing physical tension, calming autonomic stress, and cushioning post-stimulant exhaustion without causing mental numbness.
- 200 mcg
- Sublingual transmucosal target dose.
- 6-8 h
- Smooth physical comfort and emotional resilience.
Sublingual partial opioid receptor modulator designed to soothe physical strain and buffer evening burnout.
Zentraxyl formulation chapter.
Caisson Pharma
Precision neurochemistry and controlled delivery kinetics, designed and formulated with the same engineering rigor as Caisson hardware and software systems.
Formulated for cognitive endurance, autonomic balance, and neurological recovery. All clinical inquiries and dossiers are handled directly through Caisson.
To reach a person directly, write to human@caissonai.co. If email does not get through, message @aicaisson on Instagram.
